Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1601-1620 of 1,694 trials

Sickle Cell Disease: Tebapivat Study

We are investigating a new medication, tebapivat, to see if it helps improve anemia in people with sickle cell disease. The study will also look at its safety and effects on fatigue and pain.

Sickle Cell Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Vitamin D3 Supplementation: Young Adults vs. Seniors

We are comparing how vitamin D3 affects young adults and seniors to find the best supplementation approach for each group. The study also examines how respiratory illnesses might influence vitamin D levels.

Healthy Participants1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatologyEndocrinologyInfectious DiseasesInternal MedicineNephrologyOphthalmologyOtolaryngologyPediatricsPsychiatryPulmonology

Gastric Cancer: Zolbetuximab with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for adults with advanced gastric cancer to see if it works better than standard therapies. This trial is for patients with specific tumor markers.

Gastric CancerMetastatic Gastric CancerGastroesophageal Junction AdenocarcinomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are evaluating a new medication for patients with advanced non-small cell lung cancer who have a specific genetic deletion. The study aims to understand how well it works and its safety compared to previous treatments.

Advanced or Metastatic Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Chronic Heart Failure: Vitamin D and Oral Iron Study

We are studying whether vitamin D combined with oral iron can improve symptoms in patients with chronic heart failure and iron deficiency. This trial compares it to standard intravenous iron treatment to see which is more effective.

Chronic Heart FailureIron Deficiency3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Plaque Psoriasis: Oral Piclidenoson Study

We are testing an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. The goal is to see if it can significantly improve skin symptoms compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Infective Endocarditis: Oral vs. Parenteral Antibiotics

We are comparing oral antibiotics to outpatient parenteral antibiotics for treating infective endocarditis. The goal is to see if oral treatment is as effective and to assess patient satisfaction and costs.

Infective Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Breast Cancer Prevention: Exemestane vs. Tamoxifen

We are comparing two low-dose medications for post-menopausal women at high risk for breast cancer to see which one may improve quality of life and hormonal balance. This study aims to understand their effects over 12 months.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Chronic Urticaria: Study of BLU-808

We are testing a new medication, BLU-808, for people with chronic inducible and spontaneous urticaria. The study aims to understand its safety and how well it may help reduce symptoms.

Chronic Urticaria3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Small-Cell Lung Cancer: Tarlatamab Combination Study

We are testing a new treatment combining tarlatamab with durvalumab, carboplatin, and etoposide for patients with untreated extensive stage small-cell lung cancer. The goal is to see if this combination helps improve survival compared to standard treatment.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Breast Cancer Treatment: Elacestrant Study

We are studying whether Elacestrant alone is as effective as Elacestrant with ovarian function suppression in premenopausal women with early-stage ER+/HER2- breast cancer. The trial also looks at the safety of these treatment options.

Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Hairy Cell Leukemia: Vemurafenib and Rituximab Study

We are exploring a new treatment combination for hairy cell leukemia that may be less toxic than standard chemotherapy. This study aims to see if it is just as effective while monitoring patient safety and quality of life.

Hairy Cell Leukaemia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Bleximenib, Venetoclax, and Azacitidine Study

We are studying a combination of three medications for people with newly diagnosed acute myeloid leukemia who cannot receive intensive chemotherapy. The aim is to see if this combination works better than the standard treatment alone.

Acute Myeloid LeukemiaConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyOncology

Prostate Cancer: JSB462 and Lutetium Combination Study

We are studying a new treatment combining JSB462 with lutetium for adult men with advanced prostate cancer. The goal is to see how well this combination works and its safety compared to standard treatment.

Metastatic Castration-Resistant Prostate Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology